Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | F13A1 | P00488 | 1/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | TGM1 | P22735 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15320717 | 1.00 | MEN1 (0.33) | MEN1KMT2AMETF13A1TGM2 | |
| SCHEMBL19733023 | 1.00 | MEN1 (0.33) | MEN1KMT2AMETF13A1TGM2 | |
| SCHEMBL19733022 | 1.00 | MEN1 (0.33) | MEN1KMT2AMETF13A1TGM2 | |
| SCHEMBL19732982 | 0.90 | PKM (0.34) | MEN1KMT2AMETF13A1TGM2 | |
| SCHEMBL19732980 | 0.90 | PKM (0.34) | MEN1KMT2AMETF13A1TGM2 | |
| SCHEMBL16553124 | 0.90 | PKM (0.34) | MEN1KMT2AMETF13A1TGM2 | |
| SCHEMBL15319501 | 0.90 | PKM (0.34) | MEN1KMT2AMETF13A1TGM2 | |
| SCHEMBL29593122 | 0.90 | PKM (0.34) | MEN1KMT2AMETF13A1TGM2 | |
| SCHEMBL16552841 | 0.90 | BCL2 (0.32) | MEN1KMT2AMETHSD11B1 | |
| SCHEMBL19733014 | 0.90 | BCL2 (0.32) | MEN1KMT2AMETHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2834239-B1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | ENTASIS THERAPEUTICS LTD (GB) | 2017-12-27 | — | — | EP | disclosed |
| US-9623014-B2 | β-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-04-18 | — | — | US | disclosed |
| US-20160175290-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2016-06-23 | — | — | US | disclosed |
| US-9309245-B2 | Beta-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2016-04-12 | — | — | US | disclosed |
| US-20150073011-A1 | Beta-Lactamase Inhibitor Compounds | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160175290-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | LCT, MGAM, SI | MEN1 3098/4885KMT2A 1304/4885MET 4558/4885 |
| US-20150073011-A1 | Beta-Lactamase Inhibitor Compounds | LCT, MGAM, SI | MEN1 3098/4885KMT2A 1304/4885MET 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.